Polyclinique Les Fleurs
- Address
- 332 Avenue Frédéric Mistral, 83190 Ollioules, France
Polyclinique Les Fleurs - Cardiovascular & Interventional Cardiology Research
Polyclinique Les Fleurs is a specialized clinical research center focused on advancing cardiovascular care through innovative therapeutic strategies. The center demonstrates particular expertise in managing complex cardiac patients requiring percutaneous coronary intervention (PCI) with concurrent antithrombotic therapy optimization.
- Antithrombotic therapy optimization in atrial fibrillation patients undergoing PCI with stent placement
- Comparative studies of anticoagulation regimens combining P2Y12 inhibitors and direct oral anticoagulants (DOACs)
- Safety and efficacy evaluation of bleeding risk reduction strategies in high-risk cardiac populations
The center's research portfolio emphasizes the critical balance between preventing thrombotic complications and minimizing bleeding risks in patients with atrial fibrillation who require coronary interventions. Through rigorous clinical trials, Polyclinique Les Fleurs contributes valuable evidence for optimizing dual and triple antithrombotic therapy regimens, with the goal of improving outcomes for patients requiring both anticoagulation for stroke prevention and antiplatelet therapy following stent implantation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Insel Gruppe AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Polyclinique Les Fleurs
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of P2Y12 Inhibitor Monotherapy Followed by Direct Oral Anticoagulant in Atrial Fibrillation Patients Post-Sirolimus-Eluting Stent Implantation | Insel Gruppe AG | Phase III | Recruiting | Dec 2024 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2024-12-16 | 2024-12-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.